-
Innovation Ranking
NewInnovation Ranking – F-Secure Oyj
WithSecure Oyj (WithSecure) formerly F-Secure Oyj, is a cybersecurity company that offers cybersecurity and storage services. The company offers cloud protection, endpoint protection, cybersecurity, network protection, advanced threat protection, unified cloud-based security platform, and vulnerability management services to businesses. It also provides cyber intelligence, cybersecurity consulting, resilience development, security assurance, partner success services, cloud security posture management, and managed detection and response solutions. The company markets products under WithSecure brand name. Its partnered with various enterprises and institutes to develop...
-
Innovation Ranking
NewInnovation Ranking – F-star Therapeutics Inc
F-star Therapeutics Inc (F-star Therapeutics), formerly Spring Bank Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company. It discovers and develops novel class of therapeutics. The company develops nucleotide-based drugs and small molecule nucleic acid hybrids. Its development pipeline products include FS118, FS120, FS222, SB 11285, among other drug candidates. The company's drug products are used in the rescuing CPI treatment failures, improving outcomes in CPI naive, PD-L1 low tumors, chemotherapy outcomes, CPI outcomes, addressing unmet needs. Its partners programs include multiple...
-
Innovation Ranking
NewInnovation Ranking – F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories,...
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Tominersen
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Tominersen report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Giredestrant
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Giredestrant report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Inavolisib
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Inavolisib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Fenebrutinib
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Fenebrutinib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Tiragolumab
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Tiragolumab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Prasinezumab
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Prasinezumab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Divarasib
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Divarasib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.